NTLA Share Price Performance
US$8.21
-6.09 (-42.59%)
67.0% undervalued intrinsic discount
US$24.85
Fair Value
Price US$8.21
AnalystConsensusTarget US$24.85
Fair ValueUS$24.85
Share Pricen/a
Intellia Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 101 Fair Values set on narratives written by author
NTLA Community Narratives
AN
Fair Value US$24.85 67.0% undervalued intrinsic discount
Paused Trials Will Drive Rebound After Resolution Of Safety Concerns
1users have liked this narrative
0users have commented on this narrative
71users have followed this narrative
Paused Trials Will Drive Rebound After Resolution Of Safety Concerns
Key Takeaways Accelerated clinical progress and expanding market opportunities position Intellia for earlier commercialization and significant long-term revenue growth. Improved financial discipline and strong clinical validation support sustainable margins, enhanced payer acceptance, and recurring revenue from commercialization and partnerships.Read more
1users have liked this narrative
0users have commented on this narrative
71users have followed this narrative
AN
US$24.85
67.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
114.5% p.a.
Profit Margin
14.36%
Future PE
52.83x
Share price in 2028
US$25.28
Recently Updated Narratives
AN
Paused Trials Will Drive Rebound After Resolution Of Safety Concerns
Fair Value: US$24.85 67.0% undervalued intrinsic discount
71 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Intellia Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -3.85
- -612.48%
- -774.94%
- 0%
About NTLA
- Founded
- 2014
- Employees
- 403
- CEO
- WebsiteView website
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
